Dr. Gupta on VEGF Inhibitors Combined with Immunotherapy in Kidney Cancer

Shilpa Gupta, MD
Published: Tuesday, May 16, 2017



Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer.

There is currently a trial focused on axitinib (Inlyta) with pembrolizumab (Keytruda) in the first-line setting, explains Gupta.

According to Gupta, since kidney cancer is a VEGF-driven disease, it makes sense to combine the different pathways.
 


Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer.

There is currently a trial focused on axitinib (Inlyta) with pembrolizumab (Keytruda) in the first-line setting, explains Gupta.

According to Gupta, since kidney cancer is a VEGF-driven disease, it makes sense to combine the different pathways.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x